Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Shares in Denmark's pharmaceutical giant Novo Nordisk (NYSE: NVO) were lower by 4% as of 11 a.m. ET today. The move comes as ...

The NNF – a philanthropic non-profit organisation that owns a controlling stake in Danish drugmaker Novo Nordisk – has been ...

Novo Nordisk has been actively pursuing licensing deals over the past six months. There are other good reasons to consider ...

Raise awareness of obesity as a chronic, multifactorial disease. Reduce stigma and myths that hinder early care. Encourage ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See why NVO stock is a buy.

In 2004, 100 citizens lived in Ørestaden of Amager. Today, almost 26,000 live in Ørestad Parish alone, Politiken reports. Just over half of all residents in Ørestad Parish are internationals, almost ...

Novo Nordisk launches Wegovy, its anti-obesity drug, in India. Targeting a large obese population, Wegovy aims to improve ...

Novo Nordisk said in a statement on Monday that direct access to Wegovy would no longer be available to Hims & Hers Health ...